- Home
- CVKD vs SPRO Comparison
CVKD vs SPRO Comparison
Compare CVKD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- SPRO
- Stock Information
- Founded
- CVKD 2022
- SPRO 2013
- Country
- CVKD United States
- SPRO United States
- Employees
- CVKD N/A
- SPRO N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- SPRO Health Care
- Exchange
- CVKD Nasdaq
- SPRO Nasdaq
- Market Cap
- CVKD 33.7M
- SPRO 33.0M
- IPO Year
- CVKD 2023
- SPRO 2017
- Fundamental
- Price
- CVKD $13.54
- SPRO $2.74
- Analyst Decision
- CVKD Strong Buy
- SPRO Buy
- Analyst Count
- CVKD 1
- SPRO 4
- Target Price
- CVKD $32.00
- SPRO $5.00
- AVG Volume (30 Days)
- CVKD 22.0K
- SPRO 11.1M
- Earning Date
- CVKD 05-08-2025
- SPRO 05-13-2025
- Dividend Yield
- CVKD N/A
- SPRO N/A
- EPS Growth
- CVKD N/A
- SPRO N/A
- EPS
- CVKD N/A
- SPRO N/A
- Revenue
- CVKD N/A
- SPRO $44,584,000.00
- Revenue This Year
- CVKD N/A
- SPRO N/A
- Revenue Next Year
- CVKD N/A
- SPRO N/A
- P/E Ratio
- CVKD N/A
- SPRO N/A
- Revenue Growth
- CVKD N/A
- SPRO N/A
- 52 Week Low
- CVKD $5.70
- SPRO $0.51
- 52 Week High
- CVKD $22.90
- SPRO $2.95
- Technical
- Relative Strength Index (RSI)
- CVKD 37.14
- SPRO 87.61
- Support Level
- CVKD $13.00
- SPRO $0.66
- Resistance Level
- CVKD $15.90
- SPRO $2.48
- Average True Range (ATR)
- CVKD 0.96
- SPRO 0.17
- MACD
- CVKD -0.13
- SPRO 0.23
- Stochastic Oscillator
- CVKD 16.62
- SPRO 91.03
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.